Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab (Q46985480)
Jump to navigation
Jump to search
scientific article published on 8 October 2013
Language | Label | Description | Also known as |
---|---|---|---|
English | Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab |
scientific article published on 8 October 2013 |
Statements
1 reference
Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab (English)
1 reference
1 reference
Fabio Da Roit
1 reference
Luca Bologna
1 reference
Claudia Ferrara
1 reference
Alessandro Rambaldi
1 reference
Christian Klein
1 reference
8 October 2013
1 reference
1 reference
122
1 reference
20
1 reference
3482-3491
1 reference
Identifiers
1 reference